Neurocognitive profiles in treatment-resistant bipolar I and bipolar II disorder depression

BMC Psychiatry

Research Article

Geir E Eide¹  Arne E Vaaler²  Gunnar Morken²  Ole A Andreassen³  Kjetil Sundet⁴  Ulrik F Malt⁵  Ute Kessler⁶  Ketil J Oedegaard⁶  Åsa Hammar⁷  Helle K Schoeyen⁸ 

[1] Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway;Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway;Department of Neuroscience, Faculty of Medicine, NTNU, Trondheim, Norway;Division of Psychiatry, St. Olav’s University Hospital, Trondheim, Norway;Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway;Institute of Clinical Medicine, University of Oslo, Oslo, Norway;Institute of Clinical Medicine, University of Oslo, Oslo, Norway;Department of Psychology, University of Oslo, Oslo, Norway;Institute of Clinical Medicine, University of Oslo, Oslo, Norway;Department of Psychosomatic Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway;Moodnet Research Group, Psychiatric Division, Haukeland University Hospital, Bergen, Norway;Department of Clinical Medicine, Section of Psychiatry, University of Bergen, Bergen, Norway;Moodnet Research Group, Psychiatric Division, Haukeland University Hospital, Bergen, Norway;Department of Clinical Medicine, Section of Psychiatry, University of Bergen, Bergen, Norway;Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway;Moodnet Research Group, Psychiatric Division, Stavanger University Hospital, Stavanger, Norway;

关键词: Bipolar disorder depression;    Cognitive functioning;    MATRICS;    IQ;    Bipolar II disorder;   

DOI  :  10.1186/1471-244X-13-105

 received in 2013-01-24, accepted in 2013-04-01,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundThe literature on the neuropsychological profiles in Bipolar disorder (BD) depression is sparse. The aims of the study were to assess the neurocognitive profiles in treatment-resistant, acutely admitted BD depression inpatients, to compare the neurocognitive functioning in patients with BD I and II, and to identify the demographic and clinical illness characteristics associated with cognitive functioning.MethodsAcutely admitted BD I (n = 19) and BD II (n = 32) inpatients who fulfilled the DSM-IV-TR criteria for a major depressive episode were tested with the MATRICS Consensus Cognitive Battery (MCCB), the Wechsler Abbreviated Scale of Intelligence, the National Adult Reading Test, and a battery of clinical measures.ResultsNeurocognitive impairments were evident in the BD I and BD II depression inpatients within all MCCB domains. The numerical scores on all MCCB-measures were lower in the BD I group than in the BD II group, with a significant difference on one of the measures, category fluency. 68.4% of the BD I patients had clinically significant impairment (>1.5 SD below normal mean) in two or more domains compared to 37.5% of the BD II patients (p = 0.045). A significant reduction in IQ from the premorbid to the current level was seen in BD I but not BD II patients. Higher age was associated with greater neurocognitive deficits compared to age-adjusted published norms.ConclusionsA high proportion of patients with therapy-resistant BD I or II depression exhibited global neurocognitive impairments with clinically significant severity. The cognitive impairments were more common in BD I compared to BD II patients, particularly processing speed. These findings suggest that clinicians should be aware of the severe neurocognitive dysfunction in treatment-resistant bipolar depression, particularly in BD I.Trial registrationTrial registration number: NCT00664976

【 授权许可】

CC BY   
© Kessler et al.; licensee BioMed Central Ltd. 2013